



# Auro Laboratories Limited

314, T. V. Industrial Estate, S.K. Ahire Marg,  
Worli, Mumbai - 400 030. India  
Tel. : + 91 22 6663 5456  
Fax : +91 22 6663 5460  
E-mail : auro@aurolabs.com  
Web : www.aurolabs.com

Reg. Off. / Mfg. Unit :  
K-56, M. I. D. C. Tarapur,  
Dist. Palghar, Maharashtra - 401506.  
CIN No. L33125MH1989PLC051910

**Date:** November 12, 2025

To,  
Listing Department  
BSE Limited  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Mumbai – 400 001.

**Ref: Security Code No./ISIN: 530233/ INE292C01011**

**Sub: Outcome of the meeting of Board of Directors dated November 12, 2025.**

Dear Sir / Madam,

Pursuant to Regulation 30 & Regulation 33 of SEBI (LODR) Regulations, 2015, we wish to inform you that the Board of Directors of the Company at their Meeting to be held on (i.e. **Wednesday, November 12, 2025**), has transacted the following business:

1. Consider and approved the Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2025 as recommended by the Audit Committee.

In this regard, we are enclosing herewith:

- Unaudited Financial Results for the quarter ended September 30, 2025.
- Limited Review Report received from the Statutory Auditors of the Company.

The Meeting of the Board of Directors commenced at 05:00 p.m. and concluded at 06:00 p.m.

The results along with the QR code will be published in the newspapers in terms of Regulation 47(1) (b) of SEBI (LODR) Regulations, 2015 in due course.

The full format of the financial results shall be available on the website of the Stock exchange where equity shares of the Company are listed i.e. [www.bseindia.com](http://www.bseindia.com) and on Company's website [www.aurolabs.com](http://www.aurolabs.com)

Kindly take the above information on records.

Thanking You,

Yours Faithfully,

For **AURO LABORATORIES LIMITED**

**SIDDHARTHA DEORAH**  
**WHOLE TIME DIRECTOR**  
**DIN: 00230796**



Encl.: A/a

# AURO LABORATORIES LIMITED

CIN NO. :- L33125MH1989PLC051910

Regd. Office : K - 56 M.I.D.C, TARAPUR

DIST. PALGHAR, MAHARASHTRA - 401506

Tel.: 022-66635456 Email. auro@aurolabs.com Web: www.aurolabs.com

## ANNEXURE - I

Part -I

(Rs. in Lakhs except EPS)

PART-1: UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH SEPTEMBER, 2025 UNDER IND AS						
Sr. No.	Particulars	Quarter Ended			Half Yearly Ended	
		30-09-2025	30-06-2025	30-09-2024	30-09-2025	30-09-2024
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Revenue from Operations	883.67	277.42	310.12	1,161.09	882.16
2	Other Income	97.58	41.65	30.79	139.23	51.07
3	Total Income (1 + 2)	981.25	319.07	340.91	1,300.32	933.23
4	Expenses					
	a. Cost of raw material consumed	615.39	124.82	(7.91)	740.21	56.97
	b. Purchase of Stock-in-trade	1.43	-	-	1.43	-
	c. Changes in inventories of finished goods, work-in-progress and stock in trade	(419.60)	(34.77)	13.48	(454.36)	123.06
	d. Employee benefits expense	145.23	49.11	105.11	194.34	214.35
	e. Finance Cost	96.23	28.07	28.23	124.30	53.24
	f. Depreciation and amortisation expenses	65.08	27.41	27.00	92.49	54.00
	g. Other Expenses	305.51	134.97	127.13	440.48	283.17
	Total Expenses (4)	809.27	329.62	293.04	1,138.88	784.79
5	Profit / (Loss) before exceptional items and tax (3 ± 4)	171.99	(10.55)	47.85	161.44	148.44
6	Exceptional items					
7	Profit / (Loss) before tax (5 ± 6)	171.99	(10.55)	47.85	161.44	148.44
8	Tax expense					
	(a) Current tax expenses for current year		-	12.04		37.36
	(b) Deferred tax	100.41	-		100.41	-
9	Profit / (Loss) for the period from continuing operation (7 ± 8)	71.58	(10.55)	35.81	61.03	111.08
10	Profit / (Loss) for discontinuing operations	-	-	-	-	-
11	Tax expense of discontinuing operations	-	-	-	-	-
12	Profit / (Loss) for discontinuing operation (after tax) (10 ± 11)	-	-	-	-	-
13	Profit / (Loss) for the period (after tax) (9 ± 12)	71.58	(10.55)	35.81	61.03	111.08
14	Other Comprehensive Income					
	A. Items that will not be reclassified subsequently to profit or loss					
	(i) Items that will not be reclassified to profit or loss	(44.80)	44.80	39.81	-	39.81
	(ii) Income tax relating to items that will not be reclassified to profit or loss	11.28	(11.28)	(10.02)	-	(10.02)
	B. Items that will be reclassified subsequently to profit or loss					
	(i) Items that will be reclassified to profit or loss					
	(ii) Income tax relating to items that will be reclassified to profit or loss					
	Total other comprehensive income /(loss), net of tax (14)	(33.52)	33.52	29.79	-	29.79
15	Total Comprehensive Income for the period [comprising Profit/(Loss) for the period (after tax) and other comprehensive income (after tax)] (13 ± 14)	38.06	22.97	65.60	61.03	140.87
16	Paid-up equity share capital (Face value of Rs. 10 each)	623.25	623.25	623.25	623.25	623.25
17	Other Equity					3,673.56
18	Earnings per share (EPS) (Face Value - Rs. 10 per Equity Shares)					
	(a) Basic	1.15	(0.17)	0.57	0.98	1.78
	(b) Diluted	1.15	(0.17)	0.57	0.98	1.78

FOR & BEHALF OF BOARD OF DIRECTORS  
AURO LABORATORIES LIMITED

(SIDDHARTHA DEORAH)  
WHOLE TIME DIRECTOR  
DIN: 00230796



Place : Mumbai  
Dated : 12th November, 2025



**AURO LABORATORIES LIMITED**

CIN NO. :- L33125MH1989PLC051910

Regd. Office : K - 56 M.I.D.C, TARAPUR

DIST. PALGHAR, MAHARASHTRA - 401506

Tel.: 022-66635456 Email. auro@aurolabs.com Web: www.aurolabs.com

**Part II- Statement of Assets and Liabilities (Ind AS)**

(Rs. In Lakhs)

Particulars		As at 30.09.2025	As at 31.03.2025
		Audited	Audited
<b>A ASSETS</b>			
<b>1. Non-Current Assets</b>			
(a) Property, Plant and Equipment		7,683.77	2,105.84
(b) Capital Work -in-Progress		1,037.29	5,647.52
(c) Investment Property		-	-
(d) Financial Assets			
(i) Investments		4.88	4.88
(ii) Loans		-	-
(iii) Others		-	-
(e) Other non-current assets		584.22	-
<b>2. Current assets</b>			
(c) Inventories		852.08	366.79
(b) Financial Assets			
(i) Investments		-	-
(ii) Trade Receivables		721.57	939.34
(iii) Cash and cash equivalents		3.54	0.03
(iv) Bank balances other than (iii) above		62.93	62.93
(v) Loans		-	-
(vi) Other Financial Assets		127.06	782.28
(c) Other Current Assets		-	-
<b>TOTAL ASSETS</b>		<b>11077.34</b>	<b>9,909.61</b>
<b>B EQUITY AND LIABILITIES</b>			
<b>1. Equity</b>			
(a) Equity Share Capital		623.25	623.25
(b) Other Equity		3,734.59	3,673.56
<b>Total Equity</b>		<b>4,357.84</b>	<b>4,296.81</b>
<b>2. Liabilities</b>			
(I) Non-Current Liabilities			
(a) Financial Liabilities			
(i) Borrowings		3,236.45	3,078.54
(ii) Trade payables			
(iii) Other Financial Liabilities		365.00	230.00
(b) Provisions			
(c) Deferred Tax Liabilities (Net)		240.52	140.11
(d) Other Non-Current Liabilities			
(II) Current Liabilities			
(a) Financial Liabilities			
(i) Borrowings		1,157.84	1,192.90
(ii) Trade Payables			
(A) Total outstanding dues of micro enterprises and small enterprises			
(B) total outstanding dues of creditors other than micro enterprises and small enterprises		1,282.38	621.34
(b) Other Current Liabilities		427.00	339.61
(c) Provisions		10.31	10.31
(d) Current Tax Liabilities (net)		-	-
<b>TOTAL EQUITY AND LIABILITIES</b>		<b>11077.34</b>	<b>9,909.61</b>

FOR & BEHALF OF BOARD OF DIRECTORS  
AURO LABORATORIES LIMITED(SIDDHARTHA DEORAH)  
WHOLE TIME DIRECTOR  
DIN: 00230796

Place : Mumbai

Dated : 12th November, 2025

**AURO LABORATORIES LIMITED**

CIN NO. :- L33125MH1989PLC051910

Regd. Office : K - 56 M.I.D.C, TARAPUR

DIST. PALGHAR, MAHARASHTRA - 401506

Tel.: 022-66635456 Email. auro@aurolabs.com Web: www.aurolabs.com

**Part III- Cash Flow Statement**

(Amount in Rs.Lakhs)

Particulars	For the half year ended 30.09.2025		For the half year ended 30.09.2024	
<b>A. Cash flow from operating activities</b>				
Net Profit / (Loss) before extraordinary items and tax		161.44		148.44
Add: Adjustments for:				
Depreciation and amortisation	92.49		54.00	
Other Non Cash Items	-		29.79	
Finance costs	124.30		53.24	
		216.79		137.02
		<b>378.22</b>		<b>285.46</b>
Less: Adjustment for:				
Interest income	1.41		-	
Dividend income	0.01		-	
		1.42		-
<b>Operating profit / (loss) before working capital changes</b>		<b>376.80</b>		<b>285.46</b>
<b>Changes in working capital:</b>				
Adjustments for (increase) / decrease in operating assets:				
Inventories	(485.29)		122.77	
Trade receivables	217.77		661.43	
Loans and advances	655.22		(45.48)	
Long-term loans and advances	-		-	
Other non-current assets	(584.22)		-	
		(196.52)		738.72
		<b>180.28</b>		<b>1,024.18</b>
Adjustments for increase / (decrease) in operating liabilities:				
Trade payables	661.04		(479.31)	
Other current liabilities	87.39		(653.71)	
Other long-term liabilities	-		-	
Short-term provisions	-		23.79	
Long-term provisions	-		-	
		748.43		(1,109.23)
		928.71		(85.05)
Cash flow from extraordinary items		-		-
<b>Cash generated from operations</b>		<b>928.71</b>		<b>(85.05)</b>
Net income tax (paid) / refunds		-		-
<b>Net cash flow from / (used in) operating activities (A)</b>		<b>928.71</b>		<b>(85.05)</b>
<b>B. Cash flow from investing activities</b>				
Capital expenditure on fixed assets, including capital advance	(1,060.19)		(717.57)	
Proceeds from sale of fixed assets			-	
Interest received				
- Others	1.41		-	
Dividend received				
- Others	0.01		-	
		(1,058.76)		(717.57)
Net income tax (paid) / refunds				(37.36)
<b>Net cash flow from / (used in) investing activities (B)</b>		<b>(1,058.76)</b>		<b>(754.93)</b>
<b>C. Cash flow from financing activities</b>				
Proceeds from long-term borrowings	157.91		799.05	
Repayment of borrowings & Net increase / (decrease) in working capital borrowings	-		-	
Proceeds from other short-term borrowings	135.00		(1.32)	
Repayment of other short-term borrowings	(35.06)		-	
Finance cost	(124.30)		(53.24)	
		133.55		744.50
Cash flow from extraordinary items		-		-
<b>Net cash flow from / (used in) financing activities (C)</b>		<b>133.55</b>		<b>744.50</b>
<b>Net increase/(decrease) in Cash &amp; cash equivalents (A+B+C)</b>		<b>3.49</b>		<b>(95.47)</b>
Cash and cash equivalents at the beginning of the year		62.97		164.88
<b>Cash and cash equivalents at the end of the year</b>		<b>66.47</b>		<b>69.41</b>

FOR &amp; BEHALF OF BOARD OF DIRECTORS

AURO LABORATORIES LIMITED

(SIDDHARTHA DEORAH)  
WHOLE TIME DIRECTOR  
DIN: 00230796

Place : Mumbai

Dated : 12th November, 2025





**Notes on financial results:-**

- 1 The Unaudited Standalone Financial Results have been prepared in accordance with the recognition and measurement principles provided in Indian Accounting Standards (IndAS 34), the provisions of the Companies Act, 2013 (the Act), as applicable and guidelines issued by the Securities and Exchange Board of India (SEBI) under SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, [SEBI (LODR) Regulations, 2015] as amended
- 2 The above results have been reviewed and recommended by the Audit Committee and approved by the Board of Directors in their meeting held on 12th November, 2025. The Statutory Auditors of the Company have carried out a Limited Review of the aforesaid results in terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- 3 In accordance with Regulation 33 of the SEBI (LODR) Regulations, 2015, the above Unaudited Standalone Financial Results of the Company are posted on Company's website ([www.aurolabs.com](http://www.aurolabs.com)) and on the website of BSE Limited ([www.bseindia.com](http://www.bseindia.com)) where the Company's shares are listed.
- 4 The Company operates in single segment i.e. "Pharmaceuticals", and hence does not have any additional disclosures to be made under Ind AS 108 on operating Segments.
- 5 Figures for the previous Period/ Year have been re-grouped/ reworked/ re-arranged wherever necessary, to make them comparable.

**FOR & BEHALF OF BOARD OF DIRECTORS  
AURO LABORATORIES LIMITED**

  
**(SIDDHARTHA DEORAH)  
WHOLE TIME DIRECTOR  
DIN: 00230796**



**Place : Mumbai**

**Dated : 12th November, 2025**

**INDEPENDENT AUDITOR'S REVIEW REPORT ON THE QUARTERLY AND HALF YEARLY  
UNAUDITED STANDALONE FINANCIAL RESULTS OF THE COMPANY PURSUANT TO  
REGULATION 33 OF SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS)  
REGULATIONS, 2015**

Review Report to  
The Board of Directors,  
AURO LABORATORIES LTD,  
Mumbai.

- 1) We have reviewed the accompanying Statement of Unaudited Standalone Financial Result of **Auro Laboratories Ltd** ("the Company") for the quarter and half year ended 30th September, 2025("the Statement"), being submitted by Company to the Stock Exchange viz. BSE Limited ("BSE") pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Regulation"), read with SEBI Circular No. CIR/CFD/CMD1/44/2019 dated 29<sup>th</sup> March, 2019 ("the Circular").
- 2) The preparation of the statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standards 34, "Interim Financial Reporting", (Ind AS 34) prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, read with the Circular is the responsibility of the Company's management and has been approved by the Board of Directors of the Company. Our responsibility is to express a conclusion on the Statement based on our review.
- 3) We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "*Review of Interim Financial Information Performed by the Independent Auditor of Entity*" ("the Standard"), issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
- 4) Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the applicable Indian Accounting Standards ("Ind AS") prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of the Regulation, read with the circular, including the manner in which it is to be disclosed or that it contains any material misstatement.

**For B.L.Dasharda & Associates**  
**Chartered Accountants**  
**Firm Registration No. :112615W**



**CA Sushant Mehta**  
**Partner**  
**Membership No. :112489**  
Place: Mumbai  
Date : 12<sup>th</sup> November, 2025  
**UDIN No: 25112489BMIVKK7198**